Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07615010
PHASE2

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Sponsor: MiNK Therapeutics

View on ClinicalTrials.gov

Summary

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

Official title: Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-05-26

Completion Date

2027-08

Last Updated

2026-06-26

Healthy Volunteers

No

Conditions

Interventions

DRUG

agenT-797

Intravenous infusion

DRUG

Placebo

Intravenous infusion

DRUG

Standard of Care (SOC)

Antimicrobial therapy and corticosteroids per applicable guidelines.

Locations (4)

UCSF Medical Center at Parnassus Heights

San Francisco, California, United States

Children's Memorial Hermann Hospital

Houston, Texas, United States

University Hospital

San Antonio, Texas, United States

First Lviv Territorial Medical Union

Lviv, Ukraine